Guttman-Yassky, E, A Blauvelt, L.F. Eichenfield, A Paller, A Armstrong, J Drew, R Gopalan, and E Simpson. 2019. “Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study”. SKIN The Journal of Cutaneous Medicine 3 (November):S41. https://doi.org/10.25251/skin.3.supp.41.